{
  "study": {
    "study_id": "Worku2023-Ethiopia-FourHospitals-2020-2021-1",
    "title": "Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus among Patients Diagnosed with Surgical Site Infection at Four Hospitals in Ethiopia",
    "authors": [
      "Seble Worku",
      "Tamrat Abebe",
      "Berhanu Seyoum",
      "Ashenafi Alemu",
      "Yidenek Shimelash",
      "Marechign Yimer",
      "Alemseged Abdissa",
      "Getachew Tesfaye Beyene",
      "Göte Swedberg",
      "Adane Mihret"
    ],
    "journal": "Antibiotics",
    "year_publication": 2023,
    "doi": "10.3390/antibiotics12121681",
    "country_list": [
      "Ethiopia"
    ],
    "country_iso3": "ETH",
    "region_classification": "ECSA",
    "surgical_specialty": [
      "general",
      "obstetrics/gynecology",
      "orthopedics"
    ],
    "language": "English",
    "data_source_type": "published_full_text",
    "ownership_type": "public"
  },
  "design": {
    "study_design": "cross_sectional",
    "randomized": false,
    "prospective": false,
    "single_center": false,
    "multi_center": true,
    "inclusion_criteria_text": "All surgical patients, regardless of age, who underwent surgery during the study period and developed signs and symptoms of surgical site infection (SSI) within 30 days were included.",
    "exclusion_criteria_text": "Patients who developed SSIs after 30 days following the operation, those who refused to participate, patients with infected burn wounds, and those on treatment were excluded.",
    "sample_frame": "patients",
    "unit_of_analysis": "patient",
    "duplicate_publication_likelihood": false
  },
  "setting": {
    "facility_level": "tertiary",
    "urban_rural": "mixed",
    "care_setting": "hospital",
    "country_specific_sites": [
      "Debre Tabor Comprehensive Specialized Hospital",
      "Tikur Anbessa Specialized Hospital",
      "Hawassa University Teaching Hospital",
      "Jimma University Teaching Hospital"
    ]
  },
  "eligibility": {
    "population": "Patients admitted for elective and emergency surgery in general surgery, gynecology/obstetric, and orthopedics wards who developed SSI within 30 days.",
    "classification": "mixed",
    "intervention": "Antimicrobial prophylaxis before or during operation; standard wound care; laboratory identification and susceptibility testing.",
    "comparator": "None specified.",
    "outcomes_reported": [
      "amr_prevalence",
      "risk_factors_effects"
    ],
    "timeframe_years": "July 2020 to August 2021",
    "setting_types": [
      "hospital",
      "surgical_unit",
      "ward"
    ],
    "included_designs": [
      "cross_sectional"
    ],
    "excluded_designs": []
  },
  "timeframe": {
    "data_collection_start_year": 2020,
    "data_collection_start_month": 7,
    "data_collection_end_year": 2021,
    "data_collection_end_month": 8,
    "follow_up_window_days": 30
  },
  "populations": [
    {
      "arm_id": "overall",
      "description": "All patients with SSI at four hospitals in Ethiopia between July 2020 and August 2021.",
      "n_participants": 752,
      "age_group": "mixed",
      "elective_emergency": "mixed",
      "wound_class": "unspecified",
      "surgical_specialties": [
        "general",
        "obstetrics/gynecology",
        "orthopedics"
      ],
      "provenance": {
        "page": 2,
        "section_heading": "Results",
        "text_snippet": "A multicenter study was conducted at four hospitals in Ethiopia. A wound culture was performed among 752 SSI patients."
      }
    }
  ],
  "definitions": {
    "ssi_definition_standard": "study_defined",
    "ssi_window_days": 30,
    "amr_definition_standard": "CLSI",
    "breakpoint_version": "CLSI 2021",
    "resistance_definition_text": "Cefoxitin disk diffusion test used as surrogate for oxacillin resistance; vancomycin resistance defined as MIC >8 µg/mL.",
    "outcome_definitions_text": "SSI defined as infection within 30 days post-operation. MRSA defined by cefoxitin resistance and/or mecA gene. VRSA defined by vancomycin MIC >8 µg/mL and vanA/vanB gene.",
    "specimen_type": [
      "wound_swab",
      "aspirate"
    ]
  },
  "lab_methods": {
    "specimen_collection_method": "Wound swabs or aspirates collected based on standard operating procedure (SOP).",
    "culture_method": "Conventional bacteriological techniques: blood agar plates, mannitol salt agar, Gram staining, catalase and coagulase tests.",
    "AST_method": [
      "disk_diffusion",
      "MIC_broth",
      "other"
    ],
    "QC_measures": "S. aureus ATCC® 25923 and ATCC® 43300 used as control strains for cefoxitin and vancomycin; sterility checks for media; 0.5 McFarland standard for inoculum.",
    "organism_identification_method": "MALDI-TOF MS for confirmation; conventional phenotypic tests.",
    "lab_capacity_notes": "All hospitals have microbiology laboratories for culture and antimicrobial sensitivity testing."
  },
  "outcomes": {
    "ssi_incidence": [],
    "amr_proportions": [
      {
        "arm_id": "overall",
        "pathogen": "Staphylococcus aureus",
        "antibiotic": "cefoxitin",
        "who_class": "critically_important",
        "n_tested": 163,
        "n_resistant": 40,
        "n_susceptible": 123,
        "ast_method": "disk_diffusion",
        "breakpoint_standard": "CLSI",
        "breakpoint_version": "CLSI 2021",
        "specimen_type": "wound_swab",
        "site": "surgical site/wound",
        "data_period": {
          "start_year": 2020,
          "end_year": 2021
        },
        "mrsa_detection_method": "Cefoxitin disk diffusion and mecA PCR",
        "resistance_gene_markers": "mecA, femA, vanA, vanB",
        "mic_unit": "µg/mL",
        "mic_breakpoint_r": 8,
        "zone_diameter_unit": "mm",
        "notes": "MRSA defined as cefoxitin-resistant (≤21 mm) and/or mecA positive.",
        "provenance": {
          "page": 3,
          "section_heading": "Results",
          "table_id": "Table 1",
          "text_snippet": "Cefoxitin\nI-Z ≥22 mm\n123 (16.4)\n123 (75.5)\nS\nMSSA\n≤21 mm\n40 (5.3)\n40 (24.5)\nR\nMRSA"
        }
      },
      {
        "arm_id": "overall",
        "pathogen": "Staphylococcus aureus",
        "antibiotic": "vancomycin",
        "who_class": "critically_important",
        "n_tested": 40,
        "n_resistant": 1,
        "n_susceptible": 39,
        "ast_method": "MIC_broth",
        "breakpoint_standard": "CLSI",
        "breakpoint_version": "CLSI 2021",
        "specimen_type": "wound_swab",
        "site": "surgical site/wound",
        "data_period": {
          "start_year": 2020,
          "end_year": 2021
        },
        "resistance_gene_markers": "vanA, vanB",
        "mic_unit": "µg/mL",
        "mic_breakpoint_r": 8,
        "notes": "Vancomycin resistance defined as MIC >8 µg/mL; no vanA or vanB genes detected.",
        "provenance": {
          "page": 3,
          "section_heading": "Results",
          "table_id": "Table 4",
          "text_snippet": "Cefoxitin and vancomycin resistance patterns of mecA carrying Staphylococci"
        }
      }
    ],
    "morbidity": [],
    "mortality": [],
    "reoperations": [],
    "readmissions": [],
    "length_of_stay": [],
    "costs": [],
    "risk_factors_effects": [
      {
        "exposure": "Age ≥61 years",
        "outcome": "amr_infection",
        "effect_measure": "aOR",
        "effect_value": 3.729,
        "ci_lower": 1.179,
        "ci_upper": 11.791,
        "p_value": 0.025,
        "adjusted": true,
        "notes": "Likelihood of MRSA SSI occurrence higher among patients aged ≥61.",
        "provenance": {
          "page": 4,
          "section_heading": "Table 3",
          "table_id": "Table 3",
          "text_snippet": "AOR = 3.729 (1.179–11.791)"
        }
      },
      {
        "exposure": "Hospital stay ≥7 days",
        "outcome": "amr_infection",
        "effect_measure": "aOR",
        "effect_value": 1.856,
        "ci_lower": 0.688,
        "ci_upper": 5.311,
        "p_value": 0.0,
        "adjusted": true,
        "notes": "Relative risk of MRSA SSI higher among patients with longer hospital stay.",
        "provenance": {
          "page": 4,
          "section_heading": "Table 3",
          "table_id": "Table 3",
          "text_snippet": "AOR = 1.856 (0.688–5.311)"
        }
      },
      {
        "exposure": "Previous antibiotic use",
        "outcome": "amr_infection",
        "effect_measure": "aOR",
        "effect_value": 3.692,
        "ci_lower": 1.059,
        "ci_upper": 2.8,
        "p_value": 0.025,
        "adjusted": true,
        "notes": "Higher risk of methicillin-resistant Staphylococci infections among those with previous antibiotic use.",
        "provenance": {
          "page": 4,
          "section_heading": "Table 3",
          "table_id": "Table 3",
          "text_snippet": "AOR = 3.692 (1.059–2.800)"
        }
      },
      {
        "exposure": "Antimicrobial prophylaxis during operation",
        "outcome": "amr_infection",
        "effect_measure": "aOR",
        "effect_value": 3.066,
        "ci_lower": 1.101,
        "ci_upper": 9.392,
        "p_value": 0.05,
        "adjusted": true,
        "notes": "Likelihood of SSI occurrence higher among patients who had antimicrobial prophylaxis during the operation.",
        "provenance": {
          "page": 4,
          "section_heading": "Table 3",
          "table_id": "Table 3",
          "text_snippet": "AOR = 3.066 (1.101–9.392)"
        }
      }
    ]
  },
  "interventions": [],
  "stewardship_guidelines": [],
  "policy_capacity": [],
  "qualitative_thematic": {
    "codes": [
      {
        "theme": "amr_prevalence",
        "subtheme": "resistance patterns and rates by pathogen/antibiotic",
        "summary": "MRSA prevalence among S. aureus isolates was 24.5%, with 27.5% of methicillin-resistant Staphylococci carrying the mecA gene; vancomycin resistance was rare.",
        "evidence_quotes": [
          {
            "quote": "S. aureus was identified in 21.6% of participants, with 24.5% of these being methicillin-resistant Staphylococci and 0.6% showing vancomycin resistance.",
            "page": 1,
            "section": "Abstract"
          },
          {
            "quote": "Of all participants, 5.3% (40/752) carried bacteria characterized as MRSA, while among isolates of S. aureus, the frequency of MRSA was 24.5%.",
            "page": 3,
            "section": "Results"
          }
        ],
        "location_context": "Ethiopia, four tertiary hospitals",
        "confidence": "high",
        "provenance": {
          "page": 1,
          "section_heading": "Abstract",
          "text_snippet": "S. aureus was identified in 21.6% of participants, with 24.5% of these being methicillin-resistant Staphylococci and 0.6% showing vancomycin resistance."
        }
      },
      {
        "theme": "drivers_amr",
        "subtheme": "determinants (inappropriate use, IPC gaps, diagnostics delays, policy failures, supply chain, workforce, patient factors)",
        "summary": "Older age, prolonged hospital stay, previous antibiotic use, and intraoperative prophylaxis were associated with increased risk of MRSA SSI.",
        "evidence_quotes": [
          {
            "quote": "Methicillin-resistant staphylococcal infections were associated with the following risk factors: age ≥61 years, prolonged duration of hospital stay, and history of previous antibiotic use, p-values < 0.05.",
            "page": 1,
            "section": "Abstract"
          },
          {
            "quote": "The likelihood of MRSA SSI occurrence was about 3.7 times higher among patients aged ≥61 (AOR = 3.729 (1.179–11.791)) compared to those aged ≤60.",
            "page": 3,
            "section": "Results"
          }
        ],
        "location_context": "Ethiopia, four tertiary hospitals",
        "confidence": "high",
        "provenance": {
          "page": 1,
          "section_heading": "Abstract",
          "text_snippet": "Methicillin-resistant staphylococcal infections were associated with the following risk factors: age ≥61 years, prolonged duration of hospital stay, and history of previous antibiotic use, p-values < 0.05."
        }
      },
      {
        "theme": "prevention_control",
        "subtheme": "IPC programs, bundles, surveillance practices",
        "summary": "Hospitals should strengthen infection prevention and control strategies and start antimicrobial stewardship programs.",
        "evidence_quotes": [
          {
            "quote": "Hospitals should strengthen infection prevention and control strategies and start antimicrobial stewardship programs.",
            "page": 1,
            "section": "Abstract"
          }
        ],
        "location_context": "Ethiopia, four tertiary hospitals",
        "confidence": "moderate",
        "provenance": {
          "page": 1,
          "section_heading": "Abstract",
          "text_snippet": "Hospitals should strengthen infection prevention and control strategies and start antimicrobial stewardship programs."
        }
      }
    ]
  },
  "risk_of_bias": {
    "tool_used": "not_reported",
    "domain_judgements": {},
    "overall_judgement": "not_reported",
    "provenance": {}
  },
  "funding_conflicts": {
    "funding_sources": [
      "Addis Ababa University",
      "Armauer Hansen Research Institute",
      "SIDA/SAREC bilateral research cooperation with Ethiopia",
      "Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa)"
    ],
    "conflicts_of_interest": "The authors declare no competing interest.",
    "role_of_funder": "The funders had no role in the design of this study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.",
    "provenance": {
      "page": 13,
      "section_heading": "Funding",
      "text_snippet": "Funding: Collection of samples and laboratory work in Ethiopia was covered by grants from Addis Ababa University, and Armauer Hansen Research Institute. For work in Sweden, grants from SIDA/SAREC bilateral research cooperation with Ethiopia (5108013506) and the Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa) were used to cover travel and subsistence for SW during a three-month visit. Laboratory work in Sweden was done without external grants."
    }
  },
  "notes_flags": [
    {
      "type": [
        "missing_data"
      ],
      "detail": "SSI incidence (events and denominator) not directly reported; only S. aureus isolation and MRSA rates among isolates provided.",
      "provenance": {
        "page": 3,
        "section_heading": "Results",
        "table_id": "Table 1",
        "text_snippet": "S. aureus was isolated from 21.7% (163) of these participants."
      }
    },
    {
      "type": [
        "missing_data"
      ],
      "detail": "No data on mortality, reoperations, readmissions, length of stay, or costs.",
      "provenance": {
        "page": 3,
        "section_heading": "Results",
        "text_snippet": "No mention of these outcomes in results or tables."
      }
    },
    {
      "type": [
        "unit_unclear"
      ],
      "detail": "Wound class not specified for overall population; only 'clean/clean contaminated' and 'contaminated' for S. aureus subset.",
      "provenance": {
        "page": 3,
        "section_heading": "Table 2",
        "table_id": "Table 2",
        "text_snippet": "Type of surgery\nClean/Clean contaminated surgery\n148 (90.8)\nContaminated surgery\n15 (9.2)"
      }
    }
  ],
  "provenance_index": [
    {
      "page": 1,
      "section_heading": "Abstract",
      "text_snippet": "S. aureus was identified in 21.6% of participants, with 24.5% of these being methicillin-resistant Staphylococci and 0.6% showing vancomycin resistance."
    },
    {
      "page": 3,
      "section_heading": "Results",
      "table_id": "Table 1",
      "text_snippet": "Cefoxitin\nI-Z ≥22 mm\n123 (16.4)\n123 (75.5)\nS\nMSSA\n≤21 mm\n40 (5.3)\n40 (24.5)\nR\nMRSA"
    },
    {
      "page": 4,
      "section_heading": "Table 3",
      "table_id": "Table 3",
      "text_snippet": "AOR = 3.729 (1.179–11.791)"
    },
    {
      "page": 13,
      "section_heading": "Funding",
      "text_snippet": "Funding: Collection of samples and laboratory work in Ethiopia was covered by grants from Addis Ababa University, and Armauer Hansen Research Institute. For work in Sweden, grants from SIDA/SAREC bilateral research cooperation with Ethiopia (5108013506) and the Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa) were used to cover travel and subsistence for SW during a three-month visit. Laboratory work in Sweden was done without external grants."
    }
  ],
  "extraction_summary": {
    "completeness_score": 70,
    "missing_fields": [
      "ssi_incidence (events and denominator)",
      "mortality",
      "reoperations",
      "readmissions",
      "length_of_stay",
      "costs",
      "interventions",
      "stewardship_guidelines",
      "policy_capacity",
      "qualitative method context",
      "bed_capacity",
      "surgical_volume_per_year"
    ],
    "parser_warnings": [
      "No direct SSI incidence rate reported; only S. aureus isolation and MRSA rates among isolates.",
      "No clinical outcome data (mortality, LOS, reoperation, readmission, costs).",
      "No stewardship guideline or policy capacity details.",
      "No qualitative method context (interview/focus group details)."
    ],
    "confidence_overall": "moderate"
  }
}